Full Text View
Tabular View
No Study Results Posted
Related Studies
Gemox as First and Second Line Therapy in Unknown Primary Cancer
This study has been completed.
Study NCT00353145   Information provided by M.D. Anderson Cancer Center

First Received on July 13, 2006.   Last Updated on August 1, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Unknown Primary Neoplasms
Additional conditions recognized in this trial
Neoplasms
Neoplasms, Unknown Primary
More general conditions related to this trial
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes
Interventions listed in this trial
Gemcitabine (Gemox)
Oxaliplatin
Questionnaire
Additional drug interventions recognized in this trial
Gemcitabine
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
M.D. Anderson Cancer Center
Sanofi-Synthelabo


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services